Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 251-260

  Burns, Tammy L ^a,b   Ineck, Joseph R ^c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c CREIGHTON UNIVERSITY   (United States)

Author keywords

Analgesia; Cannabinoids; Chronic pain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AJULEMIC ACID; AM 1241; AM 374; ANTIINFLAMMATORY AGENT; ARACHIDONYL TRIFLUOROMETHYL KETONE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CODEINE; CORTICOSTEROID; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; LEVONANTRADOL; METHYL ARACHIDONYL FLUOROPHOSPHONATE; MORPHINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NONSTEROID ANTIINFLAMMATORY AGENT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANALGESIA; ANXIETY; ATAXIA; BALANCE DISORDER; BLURRED VISION; CANADA; CHRONIC PAIN; CLINICAL RESEARCH; CLINICAL TRIAL; CONFUSION; COUGHING; DISEASE EXACERBATION; DIZZINESS; DREAM; DROWSINESS; DRUG APPROVAL; DRUG DESIGN; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG TARGETING; DRUNK SENSATION; DYSGEUSIA; DYSPHORIA; EUPHORIA; FATIGUE; HALLUCINATION; HUMAN; INCREASED APPETITE; MEDLINE; MENTAL CONCENTRATION; MENTAL DISEASE; MOLECULAR MIMICRY; NAUSEA; NERVOUSNESS; NONHUMAN; PAIN; PATHOGENESIS; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; VERTIGO; VOMITING; XEROSTOMIA;

ANALGESICS, NON-NARCOTIC; ANIMALS; CANNABINOIDS; CHRONIC DISEASE; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; MEDLINE; PAIN; RECEPTORS, CANNABINOID;

EID: 33144454401     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G217     Document Type: Review

References (81)

1. Rosenberg RN. Pain 2003 (editorial). Arch Neurol 2003;60:1520.
2. Chronic pain in America: roadblocks to relief, www.ampainsoc.org/ whatsnew/toc road.htm (accessed 2005 Apr 12).
3. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-7.
4. Steele N, Gralla RJ, Braun DW, et al. Double-blind comparison of the anti-emetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980;64:219-24.
5. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
6. Rice ASC, Farquhar-Smith WP, Bridges D, Brooks JW. Cannabinoids and pain. In: Dostrovsky JO, Carr DB, Koltzenburg M, eds. Proceedings of the 10th World Congress on Pain. Vol 24. Seattle: IASP Press, 2003:437-68.
7. Grotenhermen F, Russo E, eds. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York: Haworth Integrative Healing Press, 2002.
8. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-35.
9. Controlled Substances Act of 1970. www.usdoj.gov/dea/agency/csa.htm (accessed 2005 Mar 13).
10. Gonzales, Attorney General, et al. v Raich et al. U.S. Supreme Court slip opinion no. 03-1454 (decided June 5,2005). www.supremecourtus.gov/opinions/ 04pdf/03-1454.pdf (accessed 2006 Jan 25).
11. California Secretary of State: text of Proposition 215. http://vote96.ss.ca. gov/Vote96/html/BP/215text.htm (accessed 2005 Mar 13).
12. Mechoulam R, Gaoni Y. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1967;86:1646-7.
13. McPartland J, Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 2001;1:103-32.
14. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 1973;25:363-72.
15. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002;95:103-17.
16. Product information. Marinol (dronabinol). Marietta, GA: Unimed Pharmaceuticals, October 2002.
17. Joy JE, Watson SJ, Benson JA Jr. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press, 1999.
18. Campbell JA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, Mc-Quay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:1-6.
19. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002;95:137-52.
20. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
21. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
22. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Hewlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
23. Paton WDM. Pharmacology of marijuana. Annu Rev Pharmacol 1975;15:191-220.
24. Herkenham M, Lynn AB, Johnson MR, Melvin LS, DeCosta BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-83.
25. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992;48:655-68.
26. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical localization of cannabinoid CB1 receptors in rat central nervous system. Neuroscience 1998;83:393-411.
27. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 1998;5:417-31.
28. Mackie K, Lai Y, Wextenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995;15:6552-61.
29. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992;89:3825-9.
30. 2+ channel current Am J Physiol 1999;276:H2085-93.
31. + M-current in hippocampal CA1 neurons. J Neurosci 2000;20:51-8.
32. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
33. Cabrai GA, Vasquez R. Marijuana decreases macrophage antiviral and antitumor activities. Adv Biosci 1991;80:93-105.
34. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science 1992;258:1946-9.
35. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993;36:3032-4.
36. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
37. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999;65:573-95.
38. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-8.
39. Di Marzo V, Bisogno T, DePetrocellis L, Melck D, Martin BR. Cannabimimetic fatty acid derivatives: anandamide family and other endocannabinoids. Curr Med Chem 1999;6:721-44.
40. Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998;51:173-87.
41. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-91.
42. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem 1995;270:6030-5.
43. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1996;276:585-93.
44. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by Cannabinoids. Nature 1998;395:381-3.
45. Yaksh TL. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J Clin Pharmacol 1981:21(8-9 suppl):334S-40S.
46. Walker JM, Hohmann G, Martin WJ, Strangman NM. The neurobiology of cannabinoid analgesia. Life Sci 1999;65:665-73.
47. Karst M, Sallm K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 2003:290:1757-62.
48. Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a "high." Life Sci 2004;75:1513-22.
49. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11-oic acid: a nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 1998;41:163-70.
50. Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999;82:87-96.
51. Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 1997;40:3228-33.
52. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21(8-9suppl):320S-6S.
53. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol 1981;21(8-9 suppl):43S-50S.
54. Feigenbaum JJ, Bergmann F, Richmond SA, Mechoulam R, Kloog Y, Sokolovsky M. A nonpsychotropic cannabinoid acts as a functional N-methyl D-aspartate (NMDA) receptor blocker. PNAS 1989;86:9584-7.
55. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J Immunol 1997;72:169-77.
56. Gallily R, Yamin A, Waksman Y, et al. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 1997;283:918-24.
57. Brewster ME, Pop E, Foltz RL, et al. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int J Clin Pharmacol Ther 1997;35:361-5.
58. Knoller N, Levi L, Israel Z, et al. Safety and outcome in a phase II clinical trial of dexanabinol in severe head trauma. Presented at: Congress of Neurological Surgeons, Seattle, October 7, 1998.
59. Shohami E, Novikov M, Bass R. Long term effect of HU-211, a novel noncompetitive NMDA antagonist, on motor and memory functions after closed head injury in the rat. Brain Res 1995;674:55-62.
60. Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A. Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol Chem Neuropathol 1994;23:125-35.
61. Beltramo M, Stella N, Calignano A, Lini SY, Makriannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997;277:1094-6.
62. Koutek B, Prestwich GD, Hewlett AC, et al. Inhibitors of arachidonyl ethanolamide hydrolysis. J Biol Chem 1994;269:22937-40.
63. Deutsch DG, Omeir R, Arreaza G, et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 1997;53:255-60.
64. Costa B, Colleoni M, Conti S, et al. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004;141:4-8.
65. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001;98:9371-6.
66. Compton DR, Martin BR. The effect of the enzyme inhibitor phenyl-methylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J Pharmacol Exp Ther 1997;283:1138-43.
67. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME. Cannabinoids block tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004;368:82-6.
68. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical cannabinoid antinociception: synergy with spinal sites. Pain 2003;105:11-6.
69. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001;93:239-45.
70. 2 cannabinoid receptors by AM 1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. PNAS 2003;100:10529-33.
71. Hamann W, diVadi PP. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors (letter). Lancet 1999;353:560.
72. Buggy DJ, Toogood L, Marie S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral δ-9-tetrahydrocannibinol in postoperative pain. Pain 2003;106:169-72.
73. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88.
74. Noyes R Jr, Brunk SF, Avery DAH, Canter AC. The analgesic properties of delta-9-tetrahydrocannibinol and codeine. Clin Pharmacol Ther 1975;18:84-9.
75. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-8.
76. GW Pharmaceuticals. Cannabis-based medicines-GW Pharmaceuticals. Drugs R&D 2003;4:306-9.
77. GW Pharmaceuticals home page, www.gwpharm.com (accessed 2005 Jun 16).
78. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 2003;17:21-9.
79. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34′n of 1′studies. Anaesthesia 2004;59:440-52.
80. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004;112:299-306.
81. Malan TP, Ibrahim MM, Lai J, et al. CB2 cannabinoid receptor agonists: pain relief without the psychoactive effects? Curr Opin Pharmacol 2003;3:62-7.